scholarly journals End Stage Renal Disease as a Potential Risk Factor for Retinal Vein Occlusion

Medicine ◽  
2015 ◽  
Vol 94 (47) ◽  
pp. e1960 ◽  
Author(s):  
San-Ni Chen ◽  
Te-Cheng Yang ◽  
Jian-Teng Lin ◽  
Ie-Bin Lian
Keyword(s):  
Risk Factor ◽  
Renal Disease ◽  
Retinal Vein Occlusion ◽  
Potential Risk ◽  
End Stage Renal Disease ◽  
Potential Risk Factor ◽  
Vein Occlusion ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Risk of Retinal Vein Occlusion Following End-Stage Renal Disease

Medicine ◽  
2016 ◽  
Vol 95 (16) ◽  
pp. e3474 ◽  
Author(s):  
Yuh-Shin Chang ◽  
Shih-Feng Weng ◽  
Chun Chang ◽  
Jhi-Joung Wang ◽  
Sung-Huei Tseng ◽  
...  
Keyword(s):  
Renal Disease ◽  
Retinal Vein Occlusion ◽  
End Stage Renal Disease ◽  
Vein Occlusion ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Impact of kidney transplantation on the risk of retinal vein occlusion in end-stage renal disease

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jangwook Lee ◽  
Hye Rim Choe ◽  
Sang Hyun Park ◽  
Kyung Do Han ◽  
Dong Ki Kim ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Renal Disease ◽  
Retinal Vein Occlusion ◽  
End Stage Renal Disease ◽  
Charlson Comorbidity Index Score ◽  
Vein Occlusion ◽  
Increased Risk ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

AbstractIt has been known that retinal vein occlusion (RVO) is associated with chronic kidney disease, especially end-stage renal disease (ESRD). However, little is known about the effect of kidney transplantation (KT) on RVO incidence in ESRD patients. This study aimed to compare the incidence of RVO in KT recipients (n = 10,498), matched ESRD patients (n = 10,498), and healthy controls (HCs, n = 10,498), using a long-term population-based cohort. The incidence of RVO was 2.74, 5.68, and 1.02 per 1000 patient-years, for the KT group, the ESRD group, and the HCs group, respectively. Adjusted hazard ratios for RVO development compared to the HCs group, were 1.53 and 3.21, in the KT group and the ESRD group, respectively. In the KT group, multivariable regression analysis indicated that an age over 50, a Charlson Comorbidity Index score over 4, and a history of desensitization therapy were associated with an increased risk of RVO. In summary, KT recipients have a lower risk for development of RVO than ESRD patients treated with dialysis. However, the risk is still higher compared to healthy people who have normal kidney functions.

Abstract 282: In Hospital Outcomes of Cardiac Arrest in Patient with End Stage Renal Disease

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_4) ◽  
Author(s):  
Muhammad Khan ◽  
Muhammad U Khan ◽  
Muhammad Munir
Keyword(s):  
Cardiac Arrest ◽  
Risk Factor ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
International Classification ◽  
International Classification Of Disease ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Background: End stage renal disease (ESRD) is a well-recognized risk factor for development of sudden cardiac arrest(SCA). There is limited data on outcomes after an in-hospital SCA event in ESRD patients. Methods: Data were obtained from National Inpatient Sample from January 2007 to December 2017. In-hospital SCA was identified using International Classification of Disease, 9th Revision, Clinical Modification, and International Classification of Disease, 10th Revision, Clinical Modification codes of 99.60, 99.63, and 5A12012. ESRD patients were subsequently identified using codes of 585.6 and N18.6. Propensity -matched analysis using logistic regression with SD caliper of 0.2 was used to match patients with and without ESRD. Crude and propensity-matched (PS) cohorts outcomes were calculated. Results: A total of 1,412,985 patients sustained in-hospital SCA during our study period. ESRD patients with in-hospital SCA were younger and had a higher burden of key co-morbidities. Mortality was similar in ESRD and non-ESRD patients in PS matched cohort (70.4% vs. 70.7%, p = 0.45, figure 1) with an overall downward trend over our study years (figure 2). Conclusion: In the context of in-hospital SCA, mortality is similar in ESRD and non-ESRD patients in adjusted analysis. Adequate risk factor modification could further mitigate the risk of in-hospital SCA among ESRD patients

Assessing Plasma Total Homocysteine in Patients with End-Stage Renal Disease

2007 ◽  
Vol 27 (5) ◽  
pp. 476-488 ◽  
Author(s):  
Bradley L. Urquhart ◽  
Andrew A. House
Keyword(s):  
Cardiovascular Disease ◽  
Risk Factor ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Elevated Plasma ◽  
Plasma Thcy ◽  
Total Homocysteine ◽  
Stage Renal Disease ◽  
End Stage ◽  
Plasma Total Homocysteine

Elevated plasma total homocysteine (tHcy) is a risk factor for cardiovascular disease; however, in light of several recent randomized trials, the issue of causality has been cast into doubt. Patients with end-stage renal disease are particularly interesting as they consistently have elevated tHcy and their leading causes of morbidity and mortality are related to cardiovascular disease. In the present article, we review the early evidence for the homocysteine theory of atherosclerosis, homocysteine metabolism, mechanisms of toxicity, and pertinent available clinical investigations. Where appropriate, the sparse evidence of homocysteine in peritoneal dialysis is reviewed. We conclude by addressing the difficulties associated with lowering plasma tHcy in patients with end-stage renal disease and suggest some novel methods for lowering tHcy in this resistant population. Finally, to address the issue of causality, we recommend that clinicians and scientists await the results of the FAVORIT trial before abandoning homocysteine as a modifiable risk factor for cardiovascular disease, as this study has recruited patients from a population with consistently elevated plasma tHcy who are known to respond to vitamin therapy.

Sign in / Sign up

Export Citation Format

Share Document